LOW DOSE NALTREXONE

Low Dose Naltrexone (LDN) is taken at bedtime and prescribed doses range typically between 3mg and 4.5mg, but we can compound any dose desired.  Belmar Pharmacy’s LDN Tablets are immediate release and are scored in half for easy dose titration.  LDN is only available through compounding pharmacies and LDN Tablets are available only at Belmar Pharmacy.  
 
Belmar Pharmacy is a preferred pharmacy on the website: www.lowdosenaltrexone.org.


  

Research

Clinical Practice
 
 

Zagon IS, McLaughlin PJ.  Intermittent blockade of OGFr and treatment of autoimmune disorders.  Exp Biol Med (Maywood),2018:1535370218817746. doi: 10.1177/1535370218817746.
 
Toljan K, Vrooman B.  Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization.  Med Sci (Basel), 2018;6(4).

Li Z, You Y, Griffin N, Feng J, Shan F. Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapyInt Immunopharmacol,2018;61:178-184.
 
 
Brown N, Panksepp J.  Low-dose naltrexone for disease prevention and quality of life.  Med Hypotheses, 2009; 72(3):333-337


 Multiple Sclerosis
 
Ludwig MD, Zagon IS, McLaughlin PJ.  Featured Article: Serum [Met5]-enkephalin levels are reduced in multiple sclerosis and restored by low-dose naltrexoneExp Biol Med (Maywood), 2017; 242(15):1524-1533.
 
Ludwig MD, Turel AP, Zagon IS, Mc Laughlin PJ. Long-term treatment with low dose naltrexone maintains stable health in patients with multiple sclerosis.  Mult Scler J Exp Transl Clin, 2016; 2:2055217316672242.
 
Turel AP, Oh KH, Zagon IS, McLaughlin PJ.  Low Dose Naltrexone for Treatment of Multiple Sclerosis: A Retrospective Chart Review of Safety and TolerabilityJ Clin Psychopharmacol, 2015; 35(5):609-611.
 
 
Frech T, Novak K, Revelo M, et al. Low-Dose Naltrexone for Pruritus in Systemic               Sclerosis. International Journal of Rheumatology, 2011; 2011:1-5.
 
Cree BA, Kornyeyeva E, Goodin DS.  Pilot trial of low-dose naltrexone and quality of life in multiple sclerosisAnn Neurol, 2010; 68(2):145-150.          
 
Zagon IS, Rahn KA, Turel AP, McLaughlin PJ.  Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multiple sclerosisExp Biol Med (Maywood), 2009 ; 234(11):1383-1392. 
 
Gironi M, Martinelli-Boneschi F, Sacerdote P, et al. A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. Multiple Sclerosis, 2008; 14(8):1076-1083.
 
 
  Crohn's Disease and Inflammatory Bowl Disease

Lie MRKL, van der Giessen J, Fuhler GM, et al.  Low dose Naltrexone for induction of remission in inflammatory bowel disease patients J Transl Med, 2018; 16(1):55.    
 
 
Roginsky G, Alexoff A, Ehrenpreis ED.  Initial Findings of an Open-Label Trial of Low-Dose Naltrexone for Symptomatic Mesenteric PanniculitisJ Clin Gastroenterol, 2015; 49(9):794-795.

Segal D, John K,  Macdonald J,  Nilesh C. Low Dose Naltrexone for Induction of Remission in   Crohn's Disease. Cochrane Database of Systematic Reviews, 2014; (2):CD010410. 
 
Smith J, Field D, Bingaman S, Evans R,  Mauger D.  Safety and Tolerability of Low-dose Naltrexone Therapy in Children With Moderate to Severe Crohn’s Disease. Journal of Clinical Gastroenterology, 2013; 47(4):339-345.
 
Smith JP, Field D, Bingaman SI, Evans R, Mauger DT.  Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn's disease: a pilot studyJ Clin Gastroenterol, 2013; 47(4):339-345.
 
 
Shannon A, Alkhouri N, Mayacy S, Kaplan B, Mahajan L.  Low-dose naltrexone for treatment of duodenal Crohn's disease in a pediatric patient.  Inflamm Bowel Dis, 2010 Sep;16(9):1457. 

Lichtenstein G, Hanauer S, Sandborn W. Management of Crohn's Disease in Adults. Am J Gastroenterol, 2009; 104(2):465-483.
 
Smith J, Stock H, Bingaman S, et al. Low-Dose Naltrexone Therapy Improves Active Crohn's Disease. The American Journal of Gastroenterology, 2007; 102(4):820-828.
 
 
Autism
 
Woeller, K. Autism - The Benefits of Low Dose Naltrexone. Biomedical Autism Intervention. website. http://drkurtwoeller.blogspot.com/2009/01/autism-benefits-of-low-dose-naltrexone.html. January 09, 2009. Accessed January 24, 2019.
 
Bouvard M, Leboyer M, Launay J, et al.  Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a double-blind, placebo-controlled study. Psychiatry Research, 1995; 58(3):191-201. 
 
Ing B, Au D, Poland R. Low-Dose Naltrexone Inhibits Pemoline-Induced Self-Biting Behavior in Prepubertal Rats. Journal of Child and Adolescent Psychopharmacology, 1993; 3(2):71-79.
 
Campbell M, Anderson L, Small, A, et al. Naltrexone in Autistic Children: Behavioral Symptoms and Attentional Learning. Journal of the American Academy of Child & Adolescent Psychiatry, 1993; 32(6):1283-1291.
 
Sandman C. The Opiate Hypothesis in Autism and Self-Injury. Journal of Child and Adolescent Psychopharmacology, 1990; 1(3):237-248.
 
Campbell M, Overall J, Small A, et al. Naltrexone in Autistic Children: An Acute Open Dose Range Tolerance Trial. Journal of the American Academy of Child & Adolescent Psychiatry, 1989; 28(2):200-2006.
 
 
HIV/AIDS
 
 
Abdel T, Oumar T, Sounkalo D, et al.  Impact of low dose naltrexone (LDN) on antiretroviral therapy (ART) treated HIV+ adults in Mali: A single blind randomized clinical trialJournal of AIDS and HIV Research, 2011; 3(10):189-198.
 
 
 Cancer 
 
Miskoff JA, Chaudhri M. Low Dose Naltrexone and Lung Cancer: A Case Report and Discussion.  Cureus, 2018; 10(7):e2924.        
 
 
 
Meng J, Meng Y, Plotnikoff NP, et al. Low dose naltrexone (LDN) enhances maturation of bone marrow dendritic cells (BMDCs).  Int Immunopharmacol, 2013; 17(4):1084-1089.           
 

Donahue R, McLaughlin P, Zagon I. Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatinExperimental Biology and Medicine, 2011; 236(7):883-895.
   
 Fibromyalgia 
 
Cote B, Ross B, Fortner J, Rao D.  The Use and Utility of Low-dose Naltrexone Capsules for Patients with Fibromyalgia.  Int J Pharm Compd, 2018; 22(3):252-256.
 
Metyas S, Chen CL, Yeter K, Solyman J, Arkfeld DG. Low Dose Naltrexone in the Treatment of Fibromyalgia.  Curr Rheumatol Rev, 2018;14(2):177-180.
 
 
 
Ramanathan S, Panksepp J, Johnson B.  Is fibromyalgia an endocrine/endorphin deficit disorder? Is low dose naltrexone a new treatment option?  Psychosomatics,2012; 53(6):591-594. 
  
Younger J, Mackey S. Fibromyalgia Symptoms Are Reduced by Low-Dose Naltrexone: A Pilot Study. Pain Med, 2009; 10(4):663-672.
 
 
 Pain
 
Bostick, K, McCarter A, Nykamp D.  The Use of Low-Dose Naltrexone for Chronic Pain.  The Senior Care Pharmacist, 2019; 34(1):43-46.       

 
Pineda-Farias JB, Caram-Salas NL, Salinas-Abarca AB, Ocampo J, Granados-Soto V. Ultra-Low Doses of Naltrexone Enhance the Antiallodynic Effect of Pregabalin or Gabapentin in Neuropathic Rats.  Drug Dev Res, 2017; 78(8):371-380. 
 
 
Hota D, Srinivasan A, Dutta P, Bhansali A, Chakrabarti A.  Off-Label, Low-Dose Naltrexone for Refractory Painful Diabetic Neuropathy.  Pain Med, 2016; 17(4):790-791.        
 
Sturn KM, Collin M.  Low-Dose Naltrexone: A New Therapy Option for Complex Regional Pain Syndrome Type I Patients.  Int J Pharm Compd, 2016; 20(3):197-201.      
 
 
Ghai B, Bansal D, Hota D, Shah CS.  Off-label, low-dose naltrexone for refractory chronic low back pain.  Pain Med, 2014; 15(5):883-884.          

Younger J, Parkitny L,  McLain D. The use of low-dose naltrexone (LDN) as a novel anti- inflammatory treatment for chronic pain. Clin Rheumatol, 2014; 33(4):451-459.
 
Chopra P, Cooper M.  Treatment of Complex Regional Pain Syndrome (CRPS) Using Low Dose Naltrexone (LDN). Journal of Neuroimmune Pharmacology, 2013; 8(3):470-476.
 
Largent-Milnes TM, Guo W, Wang HY, Burns LH, Vanderah TW.  Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling.  J Pain, 2008; 9(8):700-713. 
 
 
Addiction 
 
 
Mannelli P, Peindl K, Wu LT, Patkar AA, Gorelick DA.  The combination very low-dose naltrexone-clonidine in the management of opioid withdrawal.  Am J Drug Alcohol Abuse, 2012;38(3):200-205.
 
Mannelli P, Patkar AA, Peindl K, et al.  Early outcomes following low dose naltrexone enhancement of opioid detoxification.  Am J Addict, 2009;18(2):109-116.
       
Webster LR.  Oxytrex: an oxycodone and ultra-low-dose naltrexone formulation.  Expert Opin Investig Drugs, 2007; (8):1277-83.
 
Postural Orthostatic Tachycardia Syndrome (POTS)
and Mast Cell Activation Syndrome (MCAS)
 
 
 
Mood Disorders


 
Pape W, Wöller W. Low dose naltrexone in the treatment of dissociative symptomsNervenarzt, 2015; 86(3):346-351.
 
Dermatology
 
Bridgman AC, Kirchhof MG.  Treatment of psoriasis vulgaris using low-dose naltrexoneJAAD Case Rep, 2018; 4(8):827-829.       
 
Lee B, Elston D.  The Uses of Naltrexone in Dermatological ConditionsJ Am Acad Dermatol, 2018; (18)33104-9.       
 
Ekelem C, Juhasz M, Khera P, Mesinkovska NA.  Utility of Naltrexone Treatment for Chronic Inflammatory Dermatologic Conditions: A Systematic Review.   JAMA Dermatol, 2018; Doi:10.1001/jamadermatol.2018.4093.       
 
Tran T, Chen A, Worswick S. Successful treatment of dermatomyositis with low-dose naltrexone.  Dermatol Ther, 2018; 31(6):e12720.       
 
Muller G, Grieshaber R, Talley JF, Riepl M, Fellows D.Compounded Low-dose Naltrexone for the Treatment of Guttate Psoriasis: A Case Report.  Int J Pharm Compd, 2018; 22(4):270-278.     
 
Atanaskova Mesinkovska N.  Emerging Unconventional Therapies for Alopecia Areata.  J Investig Dermatol Symp Proc, 2018;19(1):S32-S33.         
 
Albers LN, Arbiser JL, Feldman RJ.Treatment of Hailey-Hailey Disease With Low-Dose Naltrexone. JAMA Dermatol, 2017; 153(10):1018-1020.         
 
Ibrahim O, Hogan SR, Vij A, Fernandez AP. Low-Dose Naltrexone Treatment of Familial Benign Pemphigus (Hailey-Hailey Disease)JAMA Dermatol, 2017; 153(10):1015-1017.
 
Strazzulla LC, Avila L, Lo Sicco K, Shapiro J.  Novel Treatment Using Low-Dose Naltrexone for Lichen Planopilaris.  J Drugs Dermatol, 2017;16(11):1140-1142.         
 
 
Diabetes mellitus

McLaughlin PJ, Cain JD, Titunick MB, Sassani JW, Zagon IS.  Topical Naltrexone Is a Safe and Effective Alternative to Standard Treatment of Diabetic Wounds.  Adv Wound Care (New Rochelle), 2017; 6(9):279-288.        
 
Sassani JW, Mc Laughlin PJ, Zagon IS.  The Yin and Yang of the Opioid Growth Regulatory System: Focus on Diabetes-The Lorenz E. Zimmerman Tribute Lecture.  J Diabetes Res, 2016; 2016:9703729. 
 
Hota D, Srinivasan A, Dutta P, Bhansali A, Chakrabarti A.  Off-Label, Low-Dose Naltrexone for Refractory Painful Diabetic Neuropathy.  Pain Med, 2016; 17(4):790-791.       
 
McLaughlin PJ, Sassani JW, Klocek MS, Zagon IS.  Diabetic keratopathy and treatment by modulation of the opioid growth factor (OGF)-OGF receptor (OGFr) axis with naltrexone: a review.  Brain Res Bull, 2010; 81(2-3):236-47.
   

  
 
 
HOME    ABOUT BELMAR    PATIENTS    CLINICIANS     CONTACT BELMAR   PRIVACY POLICY
Belmar Pharmacy  800.525.9473  I  303.763.5533  I  231 Violet Street, Suite 140  I  Golden, CO 80401